Article

Daily Medication Pearl: Mepolizumab (Nucala)

Nucala is an IL-5 antagonist monoclonal antibody (immunoglobulin G1 kappa) for the add-on maintenance treatment of adult and pediatric patients with severe asthma and with an eosinophilic phenotype.

Medication Pearl of the Day: Mepolizumab (Nucala)

Indication: Nucala is an interleukin-5 (IL-5) antagonist monoclonal antibody (immunoglobulin G1 kappa) indicated for the add-on maintenance treatment of adult and pediatric patients 6 years of age and older with severe asthma and with an eosinophilic phenotype.

Insight:

  • Dosing: 100 mg administered subcutaneously once every 4 weeks for severe asthma in patients 12 years of age and older.
  • Dosage forms: For injection 100 mg of lyophilized powder in a single-dose vial for reconstitution.
  • Adverse events: Most common adverse reactions (incidence ≥5%) include headache, injection site reaction, back pain, and fatigue.
  • Mechanism of action: Mepolizumab, by inhibiting IL-5 signaling, reduces the production and survival of eosinophils; however, the mechanism of mepolizumab action in asthma, CRSwNP, EGPA, and HES has not been definitively established.
  • Manufacturer: GlaxoSmithKline

Sources:

NUCALA (mepolizumab) for injection NUCALA (mepolizumab) injection (gskpro.com)

nucala image - Google Search

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com
Image credit: AwieDarwis | stock.adobe.com
Image credit: viperagp | stock.adobe.com
Image credit:  kitsawet | stock.adobe.com
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com